Stockreport

New CMO Appointment Strengthens AbCellera Biologics Inc. (ABCL)'s Push Into Immunology and Beyond [Yahoo! Finance]

AbCellera Biologics Inc. - Common Shares  (ABCL) 
PDF AbCellera Biologics Inc. (NASDAQ:ABCL) is entering a new phase in 2025, shifting from discovery to clinical execution with multiple first-in-human trials now underway. [Read more]